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leveland Ohio; and New York, New York
OBJECTIVES The goal of this study was to determine the relationship between established cardiovascular
risk factors and the extent of coronary atherosclerotic plaque.
BACKGROUND Few data exist correlating cardiovascular risk factors with volumetric measurements of
coronary atheroma burden in patients with coronary artery disease.
METHODS Clinical characteristics, quantitative coronary angiography, and intravascular ultrasound
(IVUS) were evaluated in subjects enrolled in a study comparing atorvastatin and pravastatin.
Plaque areas were measured at 1-mm intervals to compute atheroma volume. The percent of
cross sections with an abnormal intimal thickness (0.5 mm) was determined. Data on
cardiovascular risk factors were collected.
RESULTS In 654 subjects, atheroma volume averaged 174.5 mm3 and percent atheroma volume 38.9%.
Atherosclerosis was present in 81.2% of 25,897 cross sections. In univariate analysis, there was
a strong association between diabetes, male gender, and a history of either prior revascular-
ization or stroke with percent atheroma volume. Hypertension or prior myocardial infarction
was also predictive of more severe disease. Low-density lipoprotein and C-reactive protein
were not significant predictors of greater disease burden. In multivariate analysis, diabetes,
male gender, and a history of a prior interventional procedure remained strong predictors of
increased atheroma volume. History of stroke, non-Caucasian race, and smoking status
remained significant. Although multiple measures of IVUS disease burden were worse in
subjects with diabetes, angiographic stenosis severity was not different.
CONCLUSIONS Male gender, diabetes, and a history of prior revascularization are strong independent
predictors of atherosclerotic burden in coronary disease patients. Many risk factors did not
predict angiographic disease severity, suggesting different mechanisms drive stenosis devel-
opment and atheroma accumulation. (J Am Coll Cardiol 2006;47:1967–75) © 2006 by the
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.12.058American College of Cardiology Foundation
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tecropsy examinations typically demonstrate extensive ath-
rosclerosis in patients who succumb to coronary artery
isease (CAD) (1–3). Although the relationship between a
umber of cardiovascular risk factors and clinical event rates
s well established, it remains unclear whether the presence
f risk factors correlate with the extent of atherosclerosis.
everal groups have employed quantitative coronary angiog-
aphy (QCA), cross-sectional assessment of a single slice of
oronary artery by intravascular ultrasound (IVUS), carotid
ntimal-medial thickness, myocardial perfusion abnormali-
ies, and coronary calcification to address this question
4–8). Some of these groups have reported relationships
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005, accepted December 13, 2005.etween individual risk factors or clinical risk scores and
oth the extent and annual progression rate of plaque.
owever, none of these techniques measure the actual
olume of coronary atherosclerotic plaque.
Intravascular ultrasound is a relatively new imaging tech-
ique that generates high-quality tomographic images of
oronary atheromata (9). Using a motorized pullback appa-
atus, a series of cross-sectional plaque measurements can be
btained and summated to determine atheroma burden.
ntravascular ultrasound has been applied to study the
ffects of lipid-lowering therapy on atherosclerosis progres-
ion in patients with CAD and hyperlipidemia (10). Quan-
itative coronary angiography and IVUS were performed,
nabling systematic analysis of the relationship between a
ide variety of risk factors and plaque burden.
ETHODS
tudy design. The Reversal of Atherosclerosis with Ag-
ressive Lipid Lowering (REVERSAL) trial was a prospec-
ive, double-blind, multicenter, parallel-treatment study
omparing the effects of atorvastatin 80 mg and pravastatin
4
a
w
s
m
l
v
r
i
a
p
h
a
H
d
m
o
t
C
d
r
Q
t
P
c
p
s
s
b
w
t
b
n
w
c
s
s
t
I
e
m
a
t
m
S
i
d
e
a
i
S
I
I
p
C
F
s
1968 Nicholls et al. JACC Vol. 47, No. 10, 2006
Risk Factors and Plaque Burden May 16, 2006:1967–750 mg. Patients between the ages of 30 and 75 years, with
clinical indication for diagnostic coronary angiography
ere enrolled. Eligibility required evidence of CAD on
creening angiography, defined as the presence of one or
ore stenoses in a native coronary artery with 20%
uminal diameter narrowing by visual estimation. A “target
essel” containing a segment30 mm in length with50%
eduction in lumen diameter was selected for IVUS exam-
nation. A target vessel was considered suitable only if the
rtery had never undergone revascularization. At baseline, a
hysical examination was performed, and lipid levels and
igh-sensitivity C-reactive protein (CRP) were measured in
core laboratory (Medical Research Laboratory, Highland
eights, Kentucky). Lipid entry criteria required a low-
ensity lipoprotein (LDL) cholesterol between 125 and 210
g/dl after a 4- to 10-week washout period. The presence
f the metabolic syndrome was defined by an adaptation of
he Adult Treatment Panel (ATPIII) of the National
holesterol Education Program. Because measures of ab-
ominal girth were not recorded, this component was
eplaced by a body mass index (BMI) 30 kg/m2.
Abbreviations and Acronyms
BMI  body mass index
CAD  coronary artery disease
CRP  C-reactive protein
EEM  external elastic membrane
HDL  high-density lipoprotein
IVUS  intravascular ultrasound
LDL  low-density lipoprotein
PAV  percent atheroma volume
QCA  quantitative coronary angiography
TAV  total atheroma volumeigure 1. Method for selection of cross sections for analysis. Cross sections are o
ections illustrated for this vessel are shown at the bottom (cross sections 10, 2uantitative angiography. Coronary angiography of the
arget vessel was performed using standardized methods.
atients were pre-treated with 100 to 300 g of intra-
oronary nitroglycerin and selective contrast angiography
erformed using pre-defined acquisition angles. Mea-
urements were performed using a computer-assisted
ystem (11). Angiographic images were analyzed in a
linded core laboratory (Cleveland Clinic Foundation)
here technicians identified the segment imaged during
he IVUS procedure and subsequently measured vessel
orders to calculate luminal diameters and percent ste-
osis. Measurements were only made in the segment that
as assessed by IVUS. Comparison of the diameter of the
ontrast-filled angiographic catheter tip with its known dimen-
ions was used to calibrate the system. The percent diameter
tenosis and percent area stenosis are reported for the site with
he smallest lumen diameter.
VUS acquisition. After diagnostic angiography, the op-
rator performed a motorized IVUS pullback in a single
ajor epicardial vessel as previously described (12). After
nticoagulation with heparin, a guidewire was subselec-
ively placed in the vessel, and a 30-MHz, 2.6-F (0.87-
m) IVUS catheter (Ultracross, Boston Scientific
cimed, Inc., Maple Grove, Minnesota) was advanced
nto the target vessel. The transducer was positioned
istal to a side branch and a motorized pullback apparatus
mployed to progressively withdraw the IVUS transducer
t a pullback speed of 0.5 mm/s. During pullback, IVUS
mages were obtained at 30 frames/s and recorded on
uper-VHS videotape (Fig. 1).
VUS core laboratory analysis. Videotapes containing the
VUS pullbacks were analyzed in a core laboratory by
ersonnel blinded to all patient characteristics (Cleveland
linic Foundation). An operator digitized the videotapebtained for “slices” selected at 1-mm intervals (top). Three of the 48 cross
6, and 48).
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May 16, 2006:1967–75 Risk Factors and Plaque Burdennd selected the origin of a distal side-branch as a “fiduciary
oint” from which to begin analysis (Fig. 1). This frame was
elected as the image immediately before the takeoff of the
istal side branch. Subsequently, every 60th image in the
ullback was selected for analysis, representing a series of
ross sections spaced exactly 1 mm apart over a length of 30
o 90 mm. The final analyzed cross section is the last image
n the sequence before appearance of the left main coronary
rtery or right coronary ostium (Fig. 1).
irect IVUS measurements. Intravascular ultrasound mea-
urements were performed in accordance with the standards of
he American College of Cardiology and European Society of
ardiology (13). A calibration procedure was performed by
easuring 1-mm grid marks encoded in the IVUS image by
he scanner. For each cross section selected for analysis, the
perator performed manual planimetry to trace the leading
dges of the luminal and external elastic membrane (EEM)
orders (Fig. 2). The minimum and maximum diameters of
he vessel and the minimum and maximum intimal thicknesses
ere directly measured. A cross section was defined as athero-
clerotic if maximum intimal thickness exceeded 0.5 mm at any
oint in the vessel circumference (4 standard deviations greater
han the upper limit of normal) (14).
erived IVUS measurements. Atheroma area was calcu-
ated as EEM area minus luminal area. The total atheroma
olume (TAV) was calculated as the sum of atheroma areas
or each 1-mm cross section (13).
TAVn (EEMareaLumenarea)
s the pullback length was determined by the distance be-
ween the proximal and distal side branches, there was consid-
rable heterogeneity in the length of segment that was ana-
yzed. To compensate for this difference between subjects, aigure 2. Method for analysis of atheroma area. The left panel shows a repres
he boundaries planimetered for the external elastic membrane (EEM) and lumormalized TAV was derived for each subject by multiplication
f mean atheroma area (total volume for the subject divided by
he number of images analyzed) for a subject by the median
umber of analyzable segments for all subjects (10).
ormalized TAV
 (EEMareaLumenarea)
number of slices in pullback
median number of slices in study population
he percent atheroma volume was computed as the ratio
f sum of atheroma areas divided by the sum of EEM
reas (15).
PAV 
 (EEMareaLumenarea)
 (EEMarea)
 100
his represents the average percent of EEM area occupied
y atheroma within the examined vessel. The IVUS percent
rea stenosis was determined for the site with the smallest
umen diameter as the ratio of atheroma area divided by
EM area. For each vessel, the percentage of cross sections
eeting the predefined criteria for atherosclerosis (intimal
hickness 0.5 mm) was determined, and this value is
eported as “percent abnormal cross sections” (13).
tatistical methods. Analyses were performed using SAS
.12 software (SAS, Inc., Cary, North Carolina). Demo-
raphics and clinical characteristics are summarized for all
andomized patients. Categorical variables are described
sing frequencies, while continuous variables are reported as
edian and interquartile ranges. Univariate predictors are
eported using linear regression analysis of rank-transformed
utcome. Multivariate analysis used multiple linear regression
nalysis of rank-transformed outcome. Two regression
odel selection approaches were used. The forward regres-entative intravascular ultrasound cross section. The right panel illustrates
en. Atheroma area is calculated.
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Risk Factors and Plaque Burden May 16, 2006:1967–75ion approach initially contained no variables (null model).
nly variables with a p value 0.15 on univariate analysis
ere included. One variable was added at a time into the
ultivariate model from the most significant to the least
ignificant. Only variables that resulted in a p value 0.5,
hen comparing the current model with the previous
odel, were included. In the backward elimination ap-
roach, the multivariate model commenced including all
ariables. One variable was removed at a time, proceeding
rom the least significant to the most significant. Only
ariables with p values 0.1 were retained in the model at
ach step. This process was continued until all remaining
ariables in the model had p values 0.1.
ESULTS
atient demographics. A total of 654 patients were en-
olled in the study. Patient characteristics are summarized in
ables 1 and 2 as previously reported (10). The cohort
ncluded a relatively young median age (56 years), a history
f angina in 89.8%, history of hypertension in 67.1%, and a
istory of diabetes in 19.6%. The most significant physical
xamination finding was an increased BMI (median 29.8
g/m2). The metabolic syndrome, defined using the guide-
ines of the National Cholesterol Education Program, sub-
tituting BMI 30 kg/m2 for waist circumference, was
resent in 41.0% of patients. Laboratory parameters in-
luded median LDL cholesterol of 147 mg/dl, median
igh-density lipoprotein (HDL) of 41 mg/dl, and a median
RP of 2.9 mg/dl.
ngiographic and IVUS disease burden. Angiographic
nd IVUS measures of disease burden are summarized in
able 3. The angiogram typically contained a single lesion
ithin the examined vessel, which averaged 39% in diam-
ter stenosis and 62.8% in area stenosis at the most severely
arrowed site. By IVUS, TAV averaged 174.5 mm3 over a
edian pullback length of 36 mm, and the percent of EEM
rea occupied by atheroma for the entire vessel averaged
8.9% (percent atheroma volume). For the entire cohort,
able 1. Patient Characteristics (n  654)
emographics
Age 56 (49–63)
Male gender 456 (69.7)
Caucasian 580 (88.7)
istory
Current smoker 182 (27.8)
Past smoker 290 (44.3)
Never smoked 182 (27.8)
Diabetes 128 (19.6)
Hypertension 439 (67.1)
Angina 587 (89.8)
Prior myocardial infarction 228 (34.9)
Metabolic syndrome 268 (41.0)
Stroke 22 (3.4)
Coronary intervention before qualifying angiography 438 (67.0)
Coronary intervention between qualifying
angiography and randomization
110 (16.8)alues are n (interquartile range) or n (%).
V1.2% of all cross sections were atherosclerotic, using the
re-defined criteria of a maximum intimal thickness0.5 mm.
nivariate predictors of percent atheroma volume. Table 4
ummarizes the univariate predictors of IVUS disease bur-
en. For percent atheroma volume, there was a very strong
ssociation between presence of diabetes, male gender, and
history of prior revascularization or stroke and atheroscle-
otic burden. For percent atheroma volume, a history of a
rior myocardial infarction or hypertension and non-
aucasian race were also predictors of more severe disease.
otal cholesterol, LDL cholesterol, HDL cholesterol,
RP, and smoking were not predictors of disease severity.
nivariate predictors of normalized TAV. Univariate
redictors of normalized TAV are summarized in Table 4.
here was a very strong association between male gender,
on-Caucasian race, and a history of prior revascularization
nd atherosclerotic burden. A history of diabetes or hyper-
ension, systolic and diastolic blood pressure, HDL choles-
erol, and age were also predictors of more severe disease.
otal cholesterol, LDL cholesterol, CRP, and smoking
ere not predictors of disease severity.
able 2. Physical Examination and Laboratory Parameters (n  654)
eight, cm 172.7 (166.4–180.3)
eight, kg 89.1 (78.6–101.8)
MI, kg/m2 29.76 (26.36–33.83)
ystolic blood pressure, mm Hg 131.0 (120.0–145.0)
iastolic blood pressure, mm Hg 80.0 (71.0–86.0)
otal cholesterol, mg/dl 230.0 (208.0–253.0)
DL cholesterol, mg/dl 147.0 (133.0–166.0)
DL cholesterol, mg/dl 41.0 (36.0–48.0)
riglycerides, mg/dl 176.5 (132.0–237.0)
po B, mg/dl 152.0 (136.0–167.0)
RP*, mg/l 2.90 (1.40–6.10)
emoglobin A1C, % (n  148) 7.1 (6.0–8.1)
Based on log-scale data. Geometric  SD are presented correspondingly. Values in
arentheses indicate interquartile range.
Apo B  apolipoprotein B; BMI  body mass index; CRP  C-reactive protein;
DL  high-density lipoprotein; LDL  low-density lipoprotein.
able 3. Angiographic (QCA) and IVUS Measures of Disease
urden (n  654)
edian QCA values
(most severe stenosis in target vessel)
Percent diameter stenosis, % 39.0 (28.6–48.4)
Percent area stenosis, % 62.8 (49.1–73.3)
Minimum luminal diameter, mm 1.96 (1.64–2.36)
edian IVUS values
(most severe stenosis in target vessel)
Percent area stenosis, % 56.4 (43.0–65.2)
Minimum luminal diameter, mm 2.26 (1.88–2.71)
edian IVUS values (for entire pullback
within target vessel)
Normalized total atheroma volume
(median segment length 36 mm), mm3
174.5 (122.1–232.3)
Total atheroma volume, mm2 165.9 (113.8–238.9)
Percent atheroma volume, % 38.9 (32.2–46.2)
Mean percent of cross sections abnormal, % 81.2 (70.8–100.0)alues in parentheses indicate interquartile range.
IVUS  intravascular ultrasound; QCA  quantitative coronary angiography.
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May 16, 2006:1967–75 Risk Factors and Plaque Burdennivariate predictors of percent abnormal cross sections.
nivariate predictors of disease burden were similar, but not
dentical, to the parameters that were significant for percent
theroma volume (Table 4). Male gender, diabetes, HDL
evels, and a history of revascularization or stroke were
trong predictors. Total cholesterol, LDL cholesterol, CRP,
ypertension, and smoking were not predictors of disease
everity.
nivariate predictors of angiographic stenosis severity.
esults of QCA studies are summarized in Table 5. In
eneral, there were relatively few parameters predictive of
ngiographic disease severity, and the associations were not
s strong as observed for IVUS data. A history of prior
evascularization and a history of stroke were moderately
redictive of more severe stenoses. Non-Caucasian race was
arginally significant, and a history of prior myocardial
nfarction just failed to meet statistical significance.
ultivariate predictors of IVUS disease burden. These
ndings are summarized in Table 6. Diabetes, male gender,
nd a history of any prior procedure remained as strong
redictors of increased percent atheroma volume. Prior
troke and non-Caucasian race were weak independent
redictors of more severe disease after multivariate analyses.
urrent smoking was also a weak independent predictor of
ore severe disease, despite not being a univariate predictor.
or normalized TAV, age, male gender, non-Caucasian
ace, BMI, and a history of diabetes or prior procedures
emained as predictors. For percent abnormal cross sections,
nly diabetes and male gender remained as predictors and
able 4. Univariate Predictors of IVUS Disease Burden (n  654
Parameters
Percent Atheroma Volume
 Coeff. (95% CI) p Value*
ge 1.2 (0.2 to 2.5) 0.09
ale gender (n  456) 59.6 (31.7 to 87.5) 0.0001
on-white race (n  74) 40.5 (0.9 to 80.2) 0.045
MI 1.7 (3.8 to 0.4) 0.11
urrent smoker (n  182) 19.4 (9.5 to 48.3) 0.19
ystolic BP 0.4 (0.3 to 1.1) 0.26
iastolic BP 0.4 (0.8 to 1.7) 0.52
otal cholesterol 0.3 (0.7 to 0.1) 0.13
DL cholesterol 0.1 (0.6 to 0.3) 0.58
DL cholesterol 1 (2.3 to 0.1) 0.07
riglycerides 0.1 (0.2 to 0.1) 0.49
po B 0.3 (0.8 to 0.3) 0.36
RP 2.2 (13.9 to 9.6) 0.72
iabetes (n  128) 60.3 (28.2 to 92.3) 0.0002
ypertension (n  439) 28.8 (1.5 to 56.1) 0.04
rior MI (n  228) 28.2 (1.8 to 54.6) 0.04
ngina (n  587) 11.6 (29.9 to 53) 0.58
rior procedure (n  447) 88.3 (61.4 to 115.1) 0.0001
rior revascularization (n  438) 87.2 (60.5 to 113.8) 0.0001
troke (n  22) 121.6 (42.1 to 201) 0.003
etabolic syndrome (n  268) 1.8 (24.2 to 27.7) 0.89
 coefficient ( Coeff.), 95% confidence interval (CI) of  Coeff., and p value are ba
s the dependent variable.
Apo B  apolipoprotein B; BMI  body mass index; BP  blood pressure; CRP
DL  low-density lipoprotein; MI  myocardial infarction.aving a prior procedure was borderline significant.
gultivariate predictors of angiographic stenosis severity.
hese findings are summarized in Table 7. The strongest
redictor was a history of prior procedure. Non-Caucasian
ace remained significant in the multivariate analysis, but
Total Atheroma Volume Percent Abnormal Cross Sections
Coeff. (95% CI) p Value*  Coeff. (95% CI) p Value*
1.4 (0.1 to 2.7) 0.04 0.7 (0.6 to 2.0) 0.30
0.3 (63 to 117.6) 0.0001 65.7 (38.7 to 92.8) 0.0001
2.5 (12.9 to 92.1) 0.009 21.9 (16.9 to 60.6) 0.27
1.7 (0.4 to 3.8) 0.12 0.1 (2.2 to 1.9) 0.91
8.2 (37.2 to 20.9) 0.58 15.5 (12.8 to 43.7) 0.29
0.8 (0.1 to 1.5) 0.03 0.4 (0.3 to 1.1) 0.24
1.6 (0.4 to 2.8) 0.01 0.7 (0.5 to 1.9) 0.25
0.3 (0.7 to 0.1) 0.16 0.1 (0.5 to 0.3) 0.64
0.2 (0.7 to 0.3) 0.37 0 (0.5 to 0.4) 0.94
1.9 (3.1 to 0.7) 0.002 1.3 (2.5 to 0.2) 0.03
0 (0.1 to 0.2) 0.66 0 (0.1 to 0.2) 0.73
0.2 (0.7 to 0.4) 0.58 0.1 (0.5 to 0.6) 0.79
4.2 (16 to 7.6) 0.48 2.9 (14.3 to 8.6) 0.63
7.2 (4.8 to 69.6) 0.02 34.7 (3.2 to 66.2) 0.03
0.5 (3.2 to 57.8) 0.03 19 (7.7 to 45.6) 0.16
5.9 (20.7 to 32.4) 0.67 6 (19.9 to 31.8) 0.65
6.2 (67.6 to 15.2) 0.21 11.1 (51.4 to 29.3) 0.59
2.3 (14.5 to 70.1) 0.003 39.4 (12.4 to 66.5) 0.004
2.3 (14.8 to 69.8) 0.003 38 (11.2 to 64.8) 0.006
3.1 (37.2 to 123.2) 0.29 91.2 (13.5 to 168.9) 0.02
1.1 (4.8 to 47) 0.11 8.1 (17.1 to 33.4) 0.53
univariate least-square regression analysis using rank-transformed IVUS parameters
eactive protein; HDL  high-density lipoprotein; IVUS  intravascular ultrasound;
able 5. Univariate Predictors of Angiographic Percent Area
tenosis (n  654)
Parameters  Coeff. (95% CI) p Value*
ge 1.1 (0.3 to 2.5) 0.14
ale gender (n  456) 20.5 (9.5 to 50.4) 0.18
on-white race (n  74) 43.9 (2 to 85.8) 0.04
MI 1.5 (3.7 to 0.7) 0.19
urrent smoker (n  182) 13.1 (17.6 to 43.7) 0.40
ystolic BP 0.1 (0.9 to 0.6) 0.73
iastolic BP 0.2 (1.5 to 1.1) 0.77
otal cholesterol 0.1 (0.3 to 0.5) 0.61
DL cholesterol 0.2 (0.3 to 0.7) 0.52
DL cholesterol 0.8 (2.1 to 0.4) 0.20
riglycerides 0.1 (0.1 to 0.2) 0.40
po B 0.2 (0.3 to 0.8) 0.43
RP 0.1 (12.6 to 12.3) 0.98
iabetes (n  128) 27.2 (7.1 to 61.4) 0.12
ypertension (n  439) 9.1 (19.8 to 38.1) 0.54
rior MI (n  228) 27.3 (0.6 to 55.3) 0.055
ngina (n  587) 29.5 (73.2 to 14.2) 0.19
rior procedure (n  447) 35.6 (6.2 to 65) 0.02
rior revascularization (n  438) 38.5 (9.4 to 67.6) 0.01
troke (n  22) 65 (19.5 to 149.4) 0.13
etabolic syndrome (n  268) 7.4 (34.8 to 20) 0.60
 coefficient ( Coeff.), 95% confidence interval (CI) of  Coeff., and p value are
ased on univariate least-square regression analysis using rank-transformed angio-)

9
5






3
3
2
4
4
4
2
sed onraphic parameter as the dependent variable.
Abbreviations as in Table 1.
t
f
D
m
b
m
w
m
e
n
o
d
a
s
d
s
b
D
E
c
d
c
i
d
t
h
e
n
s
1972 Nicholls et al. JACC Vol. 47, No. 10, 2006
Risk Factors and Plaque Burden May 16, 2006:1967–75he association was moderate. Prior history of angina just
ailed to meet statistical significance.
iabetes and metabolic syndrome. Tables 8 and 9 sum-
arize the relationships between key measures of disease
urden and the presence or absence of diabetes or the
etabolic syndrome. All IVUS measures of disease burden
ere more severe in patients with diabetes, including both
easures of atheroma burden and stenosis severity. How-
ver, measures of minimum luminal diameter or percent
arrowing by angiography were no different in patients with
r without diabetes. In comparison with the cohort with
iabetes, the relationship between the metabolic syndrome
nd IVUS disease burden was weaker, with no measure
howing a significant relationship. Neither the presence of
iabetes nor the metabolic syndrome showed a statistically
Table 6. Multivariate Predictors of IVUS Dise
Parameters
Selection  Backwa
 Coeff. (95% CI)
Multivariate Predictors of
Age 1.2 (0.1 to 2.5)
Male gender 63.6 (36.7 to 90.5)
Non-white race 43.0 (5.8 to 80.2)
Current smoker 29.3 (1.7 to 56.9)
Diabetes 56.1 (25.3 to 86.9)
Prior procedure 73.1 (46.9 to 99.3)
Stroke 89.1 (14.7 to 163.4)
Multivariate Predictors of IVUS
Age 1.8 (0.5 to 3.1)
Male gender 106.5 (79.2 to 133.8)
Non-white race 65.2 (27.9 to 102.5)
BMI 3.1 (1.0 to 5.1)
Diabetes 34.1 (2.8 to 65.4)
Prior procedure 26.6 (0.3 to 52.9)
Diastolic BP —
Multivariate Predictors of IVU
Male gender 66.7 (39.5 to 93.9)
Diabetes 40.6 (9.5 to 71.7)
Prior procedure 27.3 (0.7 to 53.9)
Stroke 65.5 (10 to 141)
Non-white race —
*Variables selected by the backward approach are based on
approach are based on a significance level  0.15.
Abbreviations as in Table 4.
Table 7. Multivariate Predictors of QCA Dise
Parameters
Selection  Back
 Coeff. (95% CI)
Multivariate Predictors o
Non-white race 45.2 (3.7 to 86.7)
Angina 42.4 (86.2 to 1.4)
Prior revascularization 43.0 (13.7 to 72.3)
Stroke —
*Variables selected by the backward approach are based on
approach are based on a significance level  0.15.
Abbreviations as in Table 4.ignificant relationship to angiographic measures of disease
urden.
ISCUSSION
pidemiologic data suggest a complex relationship between
ardiovascular risk factors and clinical events in coronary
isease patients (16). However, the relationship between
ardiovascular risk factors and atherosclerotic disease burden
s more difficult to evaluate. Data from necropsy studies only
escribe the extent of disease in patients who succumb to
heir disease or suffer from fatal trauma (1–3). Investigators
ave correlated risk factors with indirect measures of ath-
rosclerotic burden, including carotid intimal-medial thick-
ess, coronary calcification, or measures of stenosis severity,
uch as angiography (6–8). These approaches have impor-
urden (n  654)
Selection  Stepwise†
alue  Coeff. (95% CI) p Value
Percent Plaque Volume
07 1.2 (0.1 to 2.5) 0.07
0001 63.6 (36.7 to 90.5) 0.0001
02 43.0 (5.8 to 80.2) 0.02
04 29.3 (1.7 to 56.9) 0.04
0004 56.1 (25.3 to 86.9) 0.0004
0001 73.1 (46.9 to 99.3) 0.0001
02 89.1 (14.7 to 163.4) 0.02
alized Total Atheroma Volume
006 1.8 (0.5 to 3.0) 0.006
0001 104.3 (76.9 to 131.7) 0.0001
0007 62.3 (24.9 to 99.7) 0.001
003 2.9 (0.9 to 5.0) 0.005
03 34.0 (2.8 to 65.2) 0.03
048 26.7 (0.4 to 53.0) 0.04
0.9 (0.3 to 2.1) 0.12
cent Abnormal Cross Sections
0001 69.3 (42.0 to 96.6) 0.0001
01 38.3 (7.1 to 69.5) 0.02
04 27.2 (0.6 to 53.8) 0.045
09 64.7 (10.7 to 140) 0.10
29.6 (8.2 to 67.4) 0.13
ificance level  0.10; †variables selected by the stepwise
urden (n  654)
* Selection  Stepwise†
Value  Coeff. (95% CI) p Value
A Percent Area Stenosis
0.03 44.43 (2.9 to 85.9) 0.04
0.06 42.6 (86.4 to 1.1) 0.06
0.004 42.7 (13.4 to 71.9) 0.005
— 65.8 (21.0 to 152.3) 0.14
ificance level  0.10; †variables selected by the stepwisease B
rd*
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May 16, 2006:1967–75 Risk Factors and Plaque Burdenant limitations. The risk factors associated with carotid
therosclerosis are different from those linked to coronary
isease (17). Coronary calcification occurs late in athero-
enesis, and angiography describes only luminal narrowing,
ot the true extent of atherosclerosis (18).
Intravascular ultrasound provides a high-resolution tech-
ique for quantitative assessment of vessel wall anatomy in
iving patients. Intravascular ultrasound provides a unique
pportunity to study the interaction of risk factors with
laque burden. This study is the first large-scale IVUS trial
easuring coronary atherosclerosis in hyperlipidemic pa-
ients. Diabetes, male gender, and a history of prior revas-
ularization were particularly strong predictors of atheroma
urden. Non-Caucasian race and a history of stroke also
emained significant in multivariate analysis. In contrast,
everal risk factors, including hypertension, hyperlipidemia,
nd CRP, were less important than expected.
The absence of a strong association between cholesterol
evels and IVUS measures of disease burden requires addi-
ional comment. Although HDL levels were predictive in
nivariate analysis, in terms of their association with TAV
nd the percentage of abnormal sections, none of the
raditionally measured lipid values were independently pre-
ictive of disease burden. The apparent lack of association
Table 8. Disease Burden in Patients With Dia
Diabetes vs. N
Percent atheroma volume 42.
Percent abnormal cross sections 96.
Normalized total atheroma volume
(mm3, median segment length 36 mm)
196.
Percent area stenosis 60.
Diabetes vs. N
Minimum luminal diameter (mm) 1.9
Percent area stenosis 65.
*p value is based on univariate least-square regression ana
dependent variables. Results expressed as median (interquart
Abbreviations as in Table 4.
Table 9. Disease Burden in the Metabolic Syn
Metabo
(n
Metabolic Syndrome vs. N
Percent atheroma volume 38.2
Percent abnormal cross sections 93.0
Normalized total atheroma volume
(mm3, median segment length 36 mm)
183.1
Percent area stenosis 55.1
Metabolic Syndrome vs. N
Minimum luminal diameter (mm) 2.00
Percent area stenosis 62.3
*p value is based on univariate least-square regression ana
dependent variables. Results expressed as median (interquartile ran
Abbreviations as in Table 4.etween lipids and atheroma burden is consistent with other
vailable data. The high degree of overlap between choles-
erol levels in patients with and without CAD is well
stablished (19). These findings suggest that the interaction
etween lipid levels and other risk factors, such as inflam-
ation or genetic susceptibility, determines whether abnor-
alities of lipid metabolism are expressed as atherosclerotic
isease. This is in contrast to previous reports of a strong
orrelation between LDL levels and serial accumulation of
theroma (4). However, that study involved IVUS assess-
ent of only one slice of the left main coronary artery in a
mall cohort of subjects. Given the multitude of etiologic
actors that promote atherogenesis, it is not all that surpris-
ng that the degree of correlation between LDL levels and
laque burden is not particularly high. The current findings
o not exclude the hypothesis that lipid levels play a role in
etermining atheroma vulnerability, but suggest that these
ffects may be independent of their impact on atheroma
olume.
It was also intriguing that CRP, an emerging biomarker
hat predicts cardiovascular risk, was not associated with
aseline measures of atherosclerotic burden. Reductions in
RP, in response to statin therapy, were recently demon-
trated to correlate with both a reduction in clinical events
Versus Patients Without Diabetes
etes
128)
No Diabetes
(n  526) p Value*
abetes (IVUS)
0–49.4) 38.3 (31.2–45.3) 0.0002
5–100.0) 91.3 (67.2–100.0) 0.03
.5–249.6) 166.7 (117.2–231.0) 0.02
3–67.2) 55.1 (42.4–65.2) 0.01
abetes (QCA)
0–2.28) 1.98 (1.66–2.38) 0.07
4–75.2) 61.9 (48.5–73.1) 0.12
sing rank-transformed IVUS or QCA parameters as the
ge).
e
yndrome
68)
No Metabolic Syndrome
(n  386) p Value*
tabolic Syndrome (IVUS)
46.3) 39.7 (31.7–46.2) 0.89
100.0) 92.1 (67.9–100.0) 0.53
–239.1) 168.6 (117.0–230.6) 0.11
64.5) 57.3 (43.9–66.1) 0.18
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2.39) 1.96 (1.63–2.32) 0.55
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Risk Factors and Plaque Burden May 16, 2006:1967–75nd inhibition of plaque progression (20,21). This finding
uggests that CRP may not be mechanistically linked to
theroma development, although reductions in its levels are
eneficial. Combining the current and recently reported
ata suggests that the degree of reduction of both LDL and
RP with statin therapy has a greater influence on change
n plaque burden, rather than their absolute levels at
aseline. While evidence continues to emerge implicating a
ivotal role for inflammatory events in CAD, it would
ppear that this association is related predominantly to
romoting plaque vulnerability.
The findings in patients with diabetes and the metabolic
yndrome are particularly noteworthy. Every IVUS measure
f atherosclerotic burden showed more disease in patients
ith diabetes. While increased cardiovascular event rates in
atients with diabetes has been described, the underlying
athophysiology remains incompletely defined. Many ab-
ormalities in vascular and hematologic function have been
escribed in diabetes resulting in endothelial dysfunction,
efective thrombolysis, and enhanced platelet activity (22).
he current study directly supports the conclusion that the
iabetic state promotes atherosclerotic plaque development
nd suggests that enhanced atheroma burden may explain a
ignificant proportion of the increased event rates noted in
orbidity and mortality trials. Interestingly, there was a
on-significant trend for an association between the meta-
olic syndrome and a greater TAV, but not percent volume,
uggesting that the increases in atheroma volume were some-
hat accommodated by adaptive coronary remodeling (23).
The relationship between cardiovascular risk factors and
ngiographic measures of disease burden is also intriguing.
nly history of prior revascularization was a strong inde-
endent predictor of angiographic stenosis severity. Non-
aucasian race remained a less strong predictor in the
ultivariate analysis. In contrast with the IVUS findings,
here was, remarkably, no relationship between diabetes or
etabolic syndrome and angiographic stenosis severity. The
imited correlation between risk factors and angiographic
isease severity as monitored by QCA suggests two possible
xplanations. Focal angiographic stenoses may be produced
y a different pattern of risk factors than global atheroma
urden. Alternatively, the dissociation between IVUS and
ngiographic measures of disease burden more likely reflects
he marked discrepancy in what each imaging modality
easures (i.e., the size of the doughnut vs. the size of the
oughnut hole). For vessels with diffuse narrowing, the
normal” reference segment may also contain substantial
theroma burden, and, consequently, percent stenosis by an-
iography will systematically underestimate disease burden
18).
A number of potential limitations of this analysis should
e noted. While all subjects had angiographic disease, the
bservations cannot be extrapolated to distinguish the abil-
ty of risk factors to predict the presence or absence of CAD.
he presence of a lipid range for inclusion in the studyntroduces a potential bias in the assessment of a relation-hip between lipid levels and plaque burden. It is uncertain
hether a relationship does in fact exist at levels of LDL
holesterol that fall outside of this range. Assessment of
laque burden was made by performing a volumetric mea-
urement of plaque through a segment of coronary artery.
hile atherosclerosis is a diffuse process, it is possible that
ithin a particular subject the extent of atheroma within the
tudied segment does not reflect the disease contained in the
emainder of that artery or coronary arterial tree in general.
he cohort is relatively young, and it is uncertain whether
imilar relationships between risk factors and plaque burden
re seen in an older population. Finally, it should be noted
hat, due to the absence of abdominal girth measurements,
n amended definition was used for metabolic syndrome
hat may have influenced its incidence and, therefore, its
otential relationship with plaque burden.
In conclusion, the present data demonstrate greater
theroma burden in patients with diabetes, men, and pa-
ients with a history of prior revascularization. In compar-
son with IVUS, there was a more limited relationship
etween risk factors and angiographic measures of disease
everity. These findings further highlight the complex
elationship promoting the translation of traditional and
merging risk factors and the incidence of cardiovascular
isease.
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